MEDICINES
PATIENT ASSISTANCE PROGRAMS
IMPORTED MEDICINES
CONTACT US
Upload
Introduction to Fasenra 30mg Injection 1ml
Fasenra 30mg Injection 1ml falls within the category of drugs known as interleukin inhibitors, containing the active component Benralizumab. This medication is employed in the treatment of severe eosinophilic asthma, a subtype of asthma triggered by elevated levels of eosinophils in the blood and airways. Additionally, it is approved for managing eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune condition impacting blood vessels and organs.
Before administering Fasenra 30mg Injection 1ml, it’s crucial to consult your doctor if you have a history of allergic reactions to specific injections or medications, possess a parasitic infection, or reside in an area where parasitic infections are prevalent, as this medication might compromise your ability to combat certain types of parasitic infections. If your asthma persists uncontrolled or exacerbates during treatment, promptly address this with your physician. It’s important to note that this medication is not intended for managing sudden asthma attacks and should not be employed as a rescue medication in such scenarios.
Only use Fasenra 30mg Injection 1ml under the guidance of your doctor. Inform your physician if you are pregnant, planning pregnancy, or suspect you might be pregnant, so they can assess whether the benefits outweigh any potential risks. It’s unclear whether this medication passes into breast milk, so consult your doctor if you are nursing. Fasenra is not recommended for children under 18, as its safety and benefits haven’t been established in this age group. Parents and caregivers should seek medical advice for appropriate asthma management and treatment options for both children and adults.
Uses of Fasenra 30mg Injection 1ml
- Treatment of severe eosinophilic asthma
Therapeutic Effects of Fasenra 30mg Injection 1ml
Fasenra 30mg Injection 1ml functions by attaching to a specific protein known as interleukin-5 receptor alpha (IL-5Rα) found on the surface of eosinophils, a type of white blood cell pivotal in the inflammation and constriction of airways in asthma. Through this binding process, the medication diminishes the quantity of eosinophils in both the bloodstream and airways, consequently mitigating airway inflammation and ameliorating asthma symptoms.
Interaction of Fasenra 30mg Injection 1ml with other drugs
Ensure your physician is aware of all medications you are taking, including prescription drugs, over-the-counter medications, dietary supplements, and herbal products. Some medications may interact with Fasenra 30mg Injection 1ml, potentially reducing its efficacy or causing unwanted side effects.
More Information about Fasenra 30mg Injection 1ml
- Store Fasenra 30mg Injection 1ml in a refrigerator at (2°C-8°C).
- Do not freeze
How to consume Fasenra 30mg Injection 1ml
Fasenra 30mg Injection 1ml will be administered via subcutaneous injection. Your doctor, nurse, or another healthcare provider will instruct you on the proper injection technique. Do not attempt to administer the medication unless you have been properly trained. The injection dosage will be determined by your doctor based on your medical condition and its severity.
Safety Advices for Fasenra 30mg Injection 1ml
Pregnancy
Do not use Fasenra 30mg Injection 1ml unless your doctor advises. Notify your physician if you are pregnant or planning to have a baby; think you may be pregnant so that your doctor may decide to give you this medicine if the expected benefits outweigh any potential risks.
Breast Feeding
It is unknown whether Fasenra 30mg Injection 1ml is safe to administer during breastfeeding. Inform your physician if you are a nursing mother.
Liver
It is unknown whether Fasenra 30mg Injection 1ml is safe for patients with liver problems. Inform your physician if you have any liver disease before starting the treatment. Contact your doctor if you experience any liver-related symptoms.
Alcohol
It is unknown whether consuming alcohol while taking Fasenra 30mg Injection 1ml is safe or not. So, consult your doctor for more information
Driving
Some side effects of Fasenra 30mg Injection 1ml may impair your ability to drive or operate machinery unlikely. It is safe to consume this drug.
Side Effects of Fasenra 30mg Injection 1ml
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious
Hypersensitivity reactions
Common
- Headache
- Sore throat
- Rashes
- Fever
- Injection site reactions
- Muscle pain
Word of Advice
Before taking Fasenra 30mg Injection 1ml, your doctor will likely assess your medical history and perform any necessary tests to determine if it is a suitable treatment for your specific condition. They will also provide you with instructions on how to take the medication properly and monitor your progress during treatment.
FAQs
Q 1. How is Fasenra 30mg Injection 1ml administered?
Fasenra 30mg Injection 1ml is administered as a subcutaneous injection (under the skin). The frequency and dosing may vary depending on the specific treatment regimen prescribed by a healthcare provider. It is usually given once every 4 to 8 weeks.
Q 2. Is Fasenra 30mg Injection 1ml a cure for asthma?
Fasenra 30mg Injection 1ml is not a cure for asthma. It is a medication designed to help manage and control severe eosinophilic asthma by reducing airway inflammation and symptoms. While it can significantly improve the quality of life for many people with severe asthma, it does not eliminate the underlying condition, and treatment may need to be continued as long as the condition persists.
Q 3. Can Fasenra 30mg Injection 1ml be used in children?
Fasenra 30mg Injection 1ml is approved for use in adolescents aged 12 years and older with severe eosinophilic asthma. Its safety and efficacy in younger children have not been established, so it is generally not prescribed for those below the approved age range.
Fact Box of Fasenra 30mg Injection 1ml
Molecule name: Benralizumab
Pharmacological class: Interleukin inhibitors
Therapeutic class: Anti-asthmatic agents
Indications: Treatment of severe eosinophilic asthma
Reviews
There are no reviews yet.